The new estimate of 57-77 million annual agitation episodes in the U.S. significantly expands the market potential for BioXcel Therapeutics' IGALMI® (dexmedetomidine sublingual film). This updated figure is a substantial increase from the company's previous estimate of 23 million annual episodes.1
Here's how this impacts IGALMI®'s market potential:
- Expanded Total Addressable Market (TAM): The new estimate more than doubles the perceived market size for agitation episodes, particularly in the at-home setting, which IGALMI® is aiming to address with an expanded label.1 This suggests a much larger pool of potential patients and treatment opportunities than previously thought.
- Correction of Prior Underestimation: BioXcel Therapeutics attributes the previous lower estimate of 23 million episodes to historical claims data, which likely underestimated the actual frequency due to a lack of approved treatment options for agitation.1 The new, higher estimate is based on recent market research and data from the SERENITY At-Home Phase 3 trial, indicating approximately three agitation episodes per month in the home setting, compared to about 1.2 episodes per patient per month from older claims data.1
- Increased Revenue Opportunity: A larger addressable market, if successfully captured through commercialization and adoption, translates directly into substantially higher potential revenue for BioXcel Therapeutics.1 The company views this expanded market as a foundation for "meaningful, long-term growth and value creation".1
- Validation of At-Home Use Strategy: IGALMI® is currently approved for acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults, administered under healthcare provider supervision.1 BioXcel Therapeutics is seeking FDA approval for at-home use, with a supplemental New Drug Application (sNDA) submission expected in early Q1 2026.1 The significantly larger estimate for at-home episodes underscores the critical unmet need and potential impact of making the treatment accessible in this setting.1
This revised market size highlights a substantial opportunity for IGALMI® to address a previously underestimated patient population experiencing agitation episodes.
